Revalgin, tablets 100 pcs

Spasmodic analgesic. A combination drug, which consists of non-narcotic analgesic – sodium metamizole (analgin), myotropic antispasmodic agent – pitophenone hydrochloride and m-cholinoblocking agent – phenpiveuria bromide.

Methamisole has analgesic, antipyretic and mild anti-inflammatory effects.

Pitophenone, like papaverine, has a direct myotropic effect on the smooth muscles of internal organs and causes them to relax.

Phenpiperinia bromide has an additional antispasmodic effect on the smooth muscles due to its m-cholinoblocking action.

Indications

Biliary dyskinesia, Toothache, Arthrosis and arthritis, Muscle pain (myalgia), Neuralgia of the trigeminal nerve, Painful menstruation (algodysmenorrhea), Migraine, Colitis, Pain after injuries and operations, Aciculosis, Colic, Lumbago, Headache, Neuralgia, Sciatica, Neuralgia (nerve pain), Myalgia (muscle pain), Back pain, Menstrual pain (algodysmenorrhea)ul>

For short-term treatment: arthralgia, myalgia, neuralgia, sciatica.

As an adjunctive medicine: pain syndrome after surgical interventions and diagnostic procedures.

Active ingredient

Sodium metamizole, Pitofenone, Phenpiperinia bromide

Composition

1 tablet contains:

The active ingredients:

metamizole sodium 500.00 mg, pitophenone hydrochloride 5.00 mg, phenpivery bromide 0.1 mg;

accessory substances: starch, lactose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, talc.

.

How to take, the dosage

Adults and adolescents over 15 years old take 1-2 tablets 2-3 times a day.

The maximum daily dose is 6 tablets. The duration of use is not more than 5 days.

• Children aged 6-8 years are prescribed 1/2 tablet.
• Children aged 9-12 years – 3/4 tablet.
• Children aged 13-15 years – 1 tablet.

Frequency of administration – 2-3 times a day.

The tablets should be taken orally, preferably after a meal.

Interaction

Simultaneous use of Revalgin with other non-narcotic analgesics may lead to mutual enhancement of toxic effects.

Tricyclic antidepressants, oral contraceptives, allopurinol impair metabolism of metamizole in the liver and increase its toxicity. Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effects of metamizole.

Concomitant use with cyclosporine reduces the blood levels of the latter.

Sedatives and tranquilizers increase the analgesic effect of Revalgin.

Consult a physician if it is necessary to use the above and other drugs simultaneously.

Special Instructions

Do not use to relieve acute abdominal pain (until the cause is clarified).

It is not recommended to take ethanol during treatment with Revalgin.

Parenteral administration is usually used in emergency cases (renal or hepatic colic) and when oral administration is not possible (or absorption from the gastrointestinal tract is impaired). Particular caution is required when administering 2 ml of the solution and more (risk of severe BP decrease). The intravenous injection should be performed slowly in the supine position and under control of BP, HR and respiratory rate.

In prolonged (more than one week) use of the drug it is necessary to monitor the peripheral blood count and the functional state of the liver.

Impact on driving and operating machinery

When using the drug, it is not recommended to drive vehicles and engage in other potentially dangerous activities requiring rapid physical and mental reaction.

Contraindications

Tablets:

• hypersensitivity (including. to pyrazolone derivatives)
• inhibition of medullary hematopoiesis,
• severe hepatic and/or renal insufficiency,
• glucose-6-phosphate dehydrogenase deficiency,
• tachyarrhythmias,
• severe angina pectoris,
• decompensated CHF,
• closed angle glaucoma,
• prostatic hyperplasia (with clinical manifestations),
• intestinal obstruction,
• megacolon,
• collapse.

Ampules:

• inhibition of medullary hematopoiesis;
• stable and unstable angina pectoris;
• chronic heart failure in decompensation stage;
• Glucose-6-phosphate dehydrogenase deficiency;
tachyarrhythmia;
• acute intermittent porphyria;
• closed-angle glaucoma;Prostatic hyperplasia (with clinical manifestations);
• intestinal obstruction and megacolon;
• collapse;
• pregnancy (first trimester and last 6 weeks);
• pregnancy (first trimester and last 6 weeks)
• lactation period;
• early childhood (<3 months or less than 5 kg body weight);
• high sensitivity to pyrazolone derivatives (butadione) and other components of the drug.

Patients with impaired hepatic or renal function, predisposition to arterial hypotension, bronchial asthma, hypersensitivity to NSAIDs or non-narcotic analgesics (including history of “aspirin triad”) should use the drug with caution and under medical supervision.

Children and adolescents under 18 years of age should use the drug only with the prescription.

Side effects

In therapeutic doses the drug is usually well tolerated.

Allergic reactions (skin rash, itching, very rarely – anaphylactic shock, urticaria), angioedema are sometimes possible.

In single cases – a burning sensation in the epigastric region, dry mouth, headache.

Dizziness, decreased blood pressure, tachycardia, cyanosis are possible.

In long-term use, hematopoiesis disorders: thrombocytopenia, leukopenia, agranulocytosis (may be manifested by the following symptoms: unexplained fever, chills, sore throat, difficulty swallowing, stomatitis, and development of vaginitis or proctitis).

If prone to bronchospasm, it is possible to provoke an attack.

In very rare cases – malignant erythema exudative (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome).

Rarely (usually with prolonged use or high doses) – renal dysfunction, oliguria, anuria, proteinuria, interstitial nephritis, staining of the purple color.

Very rare: decreased sweating, paresis of accommodation, difficulty in urination.

Local reactions: infiltrates may occur at the injection site if administered by injection.

Any side effects should be reported to the attending physician.

Overdose

Symptoms: vomiting, decreased blood pressure, drowsiness, confusion, nausea, epigastric pain, liver and kidney malfunction, seizures.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Similarities

Spazmalin, Maxigan, Spasmalgon, Bral, Spazgan